Research programme: paracrine communication inhibitors - Alba Therapeutics
Alternative Names: AT-1003Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator University of Maryland School of Medicine
- Class
- Mechanism of Action Paracrine communication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 08 Aug 2007 Preclinical trials in Asthma in USA (unspecified route)